Expression and clinical significance of absent in melanoma 2 in pancreatic cancer
Shaoxian Wu, Yuan Li, Panpan Zheng, Wenlu Xiao, Runzi Sun, Juan Liu, Lujun Chen, Binfeng Lu, Jingting Jiang
Abstract
ObjectiveTo investigate the expression of absent in melanoma 2 (AIM2) in pancreatic cancer tissues and its correlation with patients’ clinicopathological characteristics and prognosis.
MethodsThe tissue microarray and immunohistochemistry were used to examine the AIM2 expression in 94 cases of pancreatic cancer tissues and 71 cases of adjacent normal tissues. Wilcoxon rank sum test was used to compare the expression of AIM2 in pancreatic cancer and corresponding adjacent normal tissues. The chi-square test was used to analyze the relationship between the AIM2 expression in pancreatic cancer tissues and clinicopathological features of the patients. Kaplan-Meier survival analysis was performed to analyze the correlation between AIM2 expression and patients’ overall survival, and the Cox model was used to analyze the correlation between different clinical parameters and prognosis.
ResultsThe immunohistochemistry results showed that AIM2 was highly expressed in adjacent normal tissues (226.18±59.41), with no or low expression in pancreatic cancer tissues (195.37±63.08), and the difference between cancer tissues and adjacent normal tissues was statistically significant (P<0.01). The high expression rate of AIM2 in male patients (58.6%) was lower than that in female patients (80.6%, χ2=4.835, P<0.05). The high expression rate of AIM2 in patients with T1-T2 (73.0%) was higher than that in patients with T3 (45.0%, χ2=5.574, P<0.05). The proportion of AIM2 high expression in patients with distant metastasis was higher than that in patients without distant metastasis (P<0.05). The intensity of AIM2 staining was not significantly correlated with other clinicopathological features (P>0.05). Kaplan-Merier survival analysis showed that the overall survival (OS) of patients with low expression of AIM2 was significantly shorter than that of patients with high AIM2 expression [hazard ratio (HR)=1.810, 95%confidence interval (CI): 1.096-2.988, P<0.05]. Multi-factor Cox model analysis indicated that pathological grade (HR=0.575, 95%CI: 0.342-0.964, P<0.05) and AIM2 high expression (HR=1.902, 95%CI: 1.084-3.338, P<0.05) were independent prognostic factors of pancreatic cancer patients.
ConclusionAIM2 is expressed lowly in pancreatic cancer and can be used as a major factor in the prognosis evaluation of pancreatic cancer patients.
Key words:
Pancreatic cancer; Absent in melanoma 2; Tissue microarray; Prognosis
Contributor Information
Shaoxian Wu
Medical College of Soochow University, Suzhou 215000, China
Tumor Biological Treatment Center, the Third Affiliated Hospital of Soochow University, Engineering Technology Research Center for Tumor Immunotherapy of Jiangsu Province, Institute of Cell Therapy of Soochow University, Changzhou 213003, China
Yuan Li
Medical College of Soochow University, Suzhou 215000, China
Tumor Biological Treatment Center, the Third Affiliated Hospital of Soochow University, Engineering Technology Research Center for Tumor Immunotherapy of Jiangsu Province, Institute of Cell Therapy of Soochow University, Changzhou 213003, China
Panpan Zheng
Medical College of Soochow University, Suzhou 215000, China
Tumor Biological Treatment Center, the Third Affiliated Hospital of Soochow University, Engineering Technology Research Center for Tumor Immunotherapy of Jiangsu Province, Institute of Cell Therapy of Soochow University, Changzhou 213003, China
Wenlu Xiao
Medical College of Soochow University, Suzhou 215000, China
Tumor Biological Treatment Center, the Third Affiliated Hospital of Soochow University, Engineering Technology Research Center for Tumor Immunotherapy of Jiangsu Province, Institute of Cell Therapy of Soochow University, Changzhou 213003, China
Runzi Sun
Medical College of Soochow University, Suzhou 215000, China
Tumor Biological Treatment Center, the Third Affiliated Hospital of Soochow University, Engineering Technology Research Center for Tumor Immunotherapy of Jiangsu Province, Institute of Cell Therapy of Soochow University, Changzhou 213003, China
Juan Liu
Tumor Biological Treatment Center, the Third Affiliated Hospital of Soochow University, Engineering Technology Research Center for Tumor Immunotherapy of Jiangsu Province, Institute of Cell Therapy of Soochow University, Changzhou 213003, China
Lujun Chen
Tumor Biological Treatment Center, the Third Affiliated Hospital of Soochow University, Engineering Technology Research Center for Tumor Immunotherapy of Jiangsu Province, Institute of Cell Therapy of Soochow University, Changzhou 213003, China
Binfeng Lu
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh PA 15213, U S A
Jingting Jiang
Medical College of Soochow University, Suzhou 215000, China
Tumor Biological Treatment Center, the Third Affiliated Hospital of Soochow University, Engineering Technology Research Center for Tumor Immunotherapy of Jiangsu Province, Institute of Cell Therapy of Soochow University, Changzhou 213003, China